Novel Non-Invasive Diagnosis of Bladder Cancer in Urine Based on Multifunctional Nanoparticles

Jinshan Xu†, Shuxiong Zeng†, Jun Li‡, Li Gao‡, Wenjun Le‡, Xin Huang‡, Guandan Wang‡, Bingdi Chen‡*, Zhensheng Zhang†* and Chuanliang Xu†*

1Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China, 2Institute for Regenerative Medicine, Shanghai East Hospital, The Institute for Biomedical Engineering & Nano Science, Tongji University School of Medicine, Shanghai, China, 3Department of Pathology, Changhai Hospital, Naval Medical University, Shanghai, China, 4Department of Nutrition, Changhai Hospital, Naval Medical University, Shanghai, China

Objectives: Tumor cells were reported to have perpetual negative surface charges due to elevated glycolysis, and multifunctional nanoprobes (Fe3O4@SiO2, mNPs) could attach onto tumor cells via opposite surface charges. We thus evaluated whether mixing mNPs with urine could improve the sensitivity of urine cytology test (UCT).

Methods: We developed a novel UCT method by mixing urine with mNPs (Nano-cytology) to harvest more tumor cells during UCT procedures. The same voided urine sample was divided equally for the Nano-cytology and UCT assay, and evaluated by cytopathologists in a blinded way. The accuracy of UCT, Nano-cytology, and the combination of the two approaches (Nano-UCT) for detecting bladder cancer were determined.

Results: Urine samples were prospectively collected from 102 bladder cancer patients and 49 non-cancer participants from June 2020 to February 2021 in Changhai Hospital. Overall sensitivity of the Nano-cytology assay was significantly higher than that of the UCT assay (82.4 vs. 59.8%, p < .01). Sensitivity for low- and high-grade tumors was 79.1% and 39.5% (p < .01) and 84.7% and 74.6% (p = .25) for Nano-cytology and UCT, respectively. Specificity of Nano-cytology was slightly lower than that of UCT (89.8% vs. 100%, p = .022), which is mainly caused by severe urinary tract infection. In addition, Nano-UCT showed increased sensitivity with 90.2% for overall patients, and 83.7% and 94.9% for low- and high-grade tumor, respectively.

Conclusion: The Nano-cytology assay had a significantly improved sensitivity compared with UCT for detecting bladder cancer patients. It represents a promising tool for diagnosis of bladder cancer in clinical practice.

Keywords: bladder cancer, diagnosis, nanoparticles, urine cytology, nano

INTRODUCTION

Bladder cancer (BC) is the 10th most commonly diagnosed cancer worldwide (International Agency for Research on Cancer, 2021). Approximately 75% of patients with BC present with non-muscle-invasive bladder cancer (NMIBC) (Compérat et al., 2015). Patients with NMIBC have a significant risk of recurrence and progression after transurethral resection of bladder tumor (TURBT) (Babjuk
et al., 2019). As a result, patients with NMIBC need lifelong surveillance after therapy. Cystoscopy and urine cytology are the most important examinations for both diagnosis and surveillance of BC. However, cystoscopy is invasive and costly, and may miss flat lesions and carcinoma in situ (CIS) with a false-negative outcome ranging from 10% to 40% (Grossman et al., 2005). Currently, although numerous non-invasive urine biomarkers have been developed for diagnosis of UC, urine cytology test (UCT) is the only recommended liquid biopsy for surveillance of BC in different treatment guidelines for BC (Witjes et al., 2021). LCT (liquid-based cytology test) is commonly used in UCT daily practice with the advantages of being specific and non-invasive, but LCT depends on the experience of cytopathologists and the sensitivity is unsatisfactory, varying from 29% to 84% for different grades of BC, especially lower for low-grade BC (Yafi et al., 2015; Babjuk et al., 2022). Therefore, there is a clinical need to decrease the technique difficulty of LCT and improve its sensitivity.

With the rapid development of nanoscience and nanotechnology, numerous studies have focused on exploring nanomaterials for diagnosis and treatment of a myriad of cancers (Sahoo et al., 2007). Although glutamine, sialic acid, etc. can affect the surface charge of tumor cells, the most important effect is the that of glucose metabolism. Elevated glycolysis in tumor cells usually led to a higher-level secretion of lactate, which caused negative charges on the cell surfaces, while the surfaces of normal cells remain charge-neutral or slightly positive due to normal cell culture conditions to 70%–80% confluency. The culture wells were washed thoroughly with PBS, trypsin, and resuspended in medium. mNPs were added at the indicated concentrations to the cell suspensions and incubated on ice for 5 min with gentle agitation. After incubation, the NP-bound cells were captured by a permanent magnet placed against the side wall of the tube and free cells were removed by washing three times with PBS. The captured cells were released by removing the magnet and resuspended in PBS. Then, the captured cells were imaged using fluorescence microscopy (DMIL, Leica, Germany) and counted by a hemocytometer.

**Patients and Samples**

During June 2020 to February 2021, participants were prospectively recruited from Changhui Hospital. The inclusion criteria for participants with bladder cancer were as follows: patients diagnosed with bladder cancer and underwent TURBT or cystectomy for treatment; male or female ages >18 years; patients without any other tumor history; and patients who signed the informed consent form. The inclusion criteria for participants in the control group were as follows: participants without any tumor disease and willing to provide urine samples, participants who signed the informed consent, and participants without any benign urinary diseases, such as urinary stones, cystitis glandularis, interstitial cystitis, and cystitis. Exclusion criteria included patients unwilling to sign the consent form or unwilling to provide urine sample for analysis; patients who already had an indwelling catheter; and patients with incidental prostate cancer by prostate biopsy, transurethral resection of prostate, or cystectomy. Urine samples of approximately 100 ml were collected from participants at the time of hospital admission. Urine samples were divided equally for UCT and nano-cytology analysis.

**Urinary Cytology Test**

Approximately 50 ml of urine was used for UCT analysis. We used the BD-TriPath Preparatory (BD-TriPath Imaging, Burlington, NC), a liquid-based sampling technique, for the...
preparation of urine cytologic samples. Slides were prepared and processed according to the manufacturer’s protocol, and were evaluated by experienced cytopathologists blinded to the patients’ clinical information. The UCT assay was given as negative (normal cells and atypical cells were regarded as negative) and positive (suspicious tumor cells and tumor cells were regarded as positive).

**Nano-Cytology Assay**

Urine samples (50 ml) were processed for the Nano-cytology assay as soon as they were obtained. Urine was centrifuged at 600 g for 5 min. The cell pellet was resuspended in phosphate-buffered saline (×1) and centrifuged at 600 g for 5 min. Cells seeded in a 5-ml centrifuge tube were incubated with the positively or negatively charged mNPs at 4°C for 15 min. After incubation, the magnet was used to capture the cells surrounded by mNPs. All cell-mNPs incubations were performed on ice to avoid endocytic events. The captured cells were resuspended in 200 µl of phosphate-buffered saline (×1), and 20 µl of the remixed samples was placed in the cell counting plate and imaged using microscopy (Cellometer Auto 1000, Nexcelom Bioscience, United States) to look for suspicious tumor cells. If suspicious tumor cell was found, the result score value = 1; otherwise, value = 0. The rest of the captured cells were prepared and processed according to the UCT protocol (Figure 1). Cytology was evaluated by experienced cytopathologists blinded to the patients’ clinical information. The results were given as negative (N) or positive (P). Finally, a Nano-cytology modality was developed combining the value and the cytology result. The protocol could be made as follows: positive results include P1, P0, and N1; a negative result is N0.

**Statistical Analysis**

Sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were calculated for Nano-cytology, UCT, and a combination of these two methods (Nano-UCT). Subgroup analyses were performed for different tumor grades and stages. The Fisher’s test (by SPSS Statistics software, v22.0, IBM Institute) was used to determine the statistical difference for categorical variables. A p-value <.05 was considered statistically significant.

**RESULTS**

**Interaction of the mNPs With Bladder Cancer Cell**

To determine whether positively charged mNPs could bind bladder tumor cells specifically, six different bladder cancer cell lines and the Hela cell line (positive control) were incubated with positively and negatively charged mNPs, respectively. Upon electrostatic interaction with enough mNPs, the captured cells were "pulled" to the side of the tube by a magnet. Figure 2A shows that positively and negatively charged mNPs had a completely different pattern of interaction with tumor cells, and positively charged mNPs had a significantly higher ability to capture tumor cells, which was in line with our previous study (Chen et al., 2016). Furthermore, we tried to characterize the interaction of the bladder cancer cell and mNPs; a constant number of three different bladder cancer cells were incubated with various concentrations of positively charged mNPs ranging from 5 to 150 µg/ml, and with 50 µg/ml mNPs at different pH. The efficiency of the magnetic capture ability for bladder tumor cells by mNPs is shown in Figures 2B,C; 50 µg/ml positive NPs were enough to capture most of the $5 \times 10^5$ bladder cancer cells, and the mNPs...
showed stable capture efficiency with pH ranging from 6 to 9. Moreover, we demonstrated that 50 µg/ml positively charged mNPs could capture 50 tumor cells per 50 ml of urine (Figure 2D).

mNPs Formed Nano-Ring Around Bladder Tumor Cells
We transfected green fluorescent labeled lentivirus into Biu-87 cells (Figure 3A) and incubated with mNPs. As shown in Figure 3B, we found positively charged mNPs binding to and covering the surface of Biu-87 cells. The phenomenon looked like rings (nano-ring) under a microscope (Figure 3A). We further performed an experiment to validate the positively charged mNPs specifically capturing tumor cells. Labeled Biu-87 cells were mixed with the non-cancerous SVHUC cells in a ratio of 1:1 and incubated with positively charged mNPs. As displayed, nano-ring was found around Biu-87 cells, but not detected around SVHUC cells, which showed no fluorescence (Figure 3C).

The Ability of mNPs to Differentiate Tumor Cells in Primary Cultured Cells
To determine whether the nano-ring phenomenon also existed in primary cultured cells, different types of primary cells were harvested from SCID, FVB, C57, nude mice’s bladder, bladder cancer patients’ tissue, and subcutaneous xenograft tumor by T24 cells on nude mice and incubated with positively charged mNPs. No nano-ring phenomenon was found in the normal mice cells. Cells from subcutaneous xenograft tumor and patients’ tumor tissue, the nano-ring phenomena were obvious (Figures 4A–C). The mNPs bond cells were then magnetically captured and separated. Slides contained separated cells that were confirmed to be tumor cells by cytopathologists blinded to the information of cells (Figure 4D).

The Ability of mNPs to Differentiate Tumor Cells in Urine
We further investigated whether mNPs could identify tumor cells from urine and avoid the influence of red blood cells and white blood cells in urine. Urine exfoliated cells from bladder cancer patients were used to incubate with positively charged mNPs. Many cells showed the nano-ring phenomenon (Figure 4E). In Figure 4E, white blood cells were smaller than bladder cancer cells, and nano-ring was not seen. While red blood cells were found in hematuria cases due to its properties, which adheres to the tube and is hard to wipe off. However, this could be distinguished by the feature of round cake with concave center on both sides. As shown in Figure 4F, tumor cells with nano-ring were detected and confirmed by cytopathologists.

Nano-Cytology Showed Improved Sensitivity Compared With Urine Cytology Test
One hundred and six patients and 49 controls were enrolled to compare the sensitivity between nano-cytology and traditional UCT assays. Four participants were excluded due to the incidental prostate cancer found after cystectomy. Detailed information of

![Figure 2](https://example.com/figure2.png)

**FIGURE 2** Interaction of the mNPs with bladder tumor cells. (A) Positive mNPs and negative mNPs have completely different patterns of interaction with bladder tumor cells. *****p < .001. (B) The magnetic capture efficiencies of bladder tumor cells by NPs of positive charges are plotted at various mNP concentrations. (C) The magnetic capture efficiencies of bladder tumor cells by mNPs of positive charges are plotted at various pH value. (D) Positive mNPs can capture cancer cell if more than 50 cells in 50-ml samples were given.
included participants is shown in Table 1. Compared with UCT, nano-cytology identified BC with significantly improved overall sensitivity (82.4% vs. 59.8%, \( p < .01 \)), but slightly lower specificity (89.8% vs. 100%, \( p = .022 \), Table 2). Nano-cytology resulted in higher sensitivity for identifying low-grade (79.1% vs. 39.5%, \( p < .01 \)) and high-grade BC (84.7% vs. 74.6%, \( p = .25 \)) compared with UCT.
Moreover, the advantage of nano-cytology was maintained in the detection of NMIBC (82.4 vs. 56.5%, \( p < .01 \)), but there was no difference between muscle-invasive BC (82.4% vs. 76.5%, \( p = 1 \)). When combining these two methods together, nano-UCT resulted in a sensitivity of 90.2%, a specificity of 89.8%, a PPV of 94.8%, and an NPV of 81.5% (Table 3).

**DISCUSSION**

In the present study, we found that positively charged mNPs could specifically capture bladder tumor cells in urine, and tumor cells that bond with mNPs could be enriched under the influence of a magnet. The patient exfoliated cells that showed the nano-ring phenomenon should be regarded as suspicious tumor cells and tumor cells. The sensitivity of standard UCT for detecting urothelial carcinoma is low, largely due to its inability to process the entire sample, paucicellularity, and the presence of background cells (Miyake et al., 2021). Our novel approach could help to reduce the confounding background cells such as normal urothelial cells, apoptotic cells, and red and white blood cells in urine. Cytopathologists thus could focus on evaluating suspicious cells captured by mNPs. As a result, our study showed that nano-cytology had a significantly higher sensitivity (82.4% vs. 59.8%), especially for low-grade tumor cells (79.1% vs. 39.5%), and comparable specificity compared with traditional UCT. In addition, the mNPs are cost-effective, which can be synthesized at a cost of $100 and test tens of thousands of samples. So there is not much difference between nano-cytology and UCT in terms of cost.

Urine cytology is a commonly used noninvasive approach for detecting tumor cells in the urinary tract with high specificity. Currently, UCT is recommended in the surveillance of high-risk NMIBC in clinical guidelines at certain intervals (Babjuk et al., 2019). However, the sensitivity of UCT varied from 29% to 84% for tumors of different grades and stages (Dimashkieh et al., 2013), and the sensitivity for detecting CIS was 28%–100% (Babjuk et al., 2022). Meanwhile, the accuracy of UCT largely depends on the experience and skill of the technicians and cytopathologists. The Paris System for Reporting Urinary Cytology have been put forward to standardize the reporting system of UCT (Babjuk et al., 2022). Meilleroux et al. (2018) reported that the Paris System helped to characterize the atypical

### TABLE 1 | Patient baseline characteristics.

| Urine samples   | Tumor       | Control     | \( p \)-value |
|-----------------|-------------|-------------|--------------|
| Participants included | 102         | 49          |              |
| Participants excluded | 4           |             | .601         |
| Gender          |             |             |              |
| Male            | 87          | 41          |              |
| Female          | 15          | 8           |              |
| Age Mean (SD)   | 66.51 (12.31) | 66.24 (13.55) | .354        |
| Tumor stage     |             |             |              |
| \(<pT2\)        | 85          |             |              |
| \(\geq pT2\)    | 17          |             |              |
| Tumor grade     |             |             |              |
| Low             | 43          |             |              |
| High            | 59          |             |              |
| Benign urinary diseases in control |           |             |              |
| Urinary stones  | 13          |             |              |
| Benign prostate hyperplasia | 21        |             |              |
| Incontinence    | 4           |             |              |
| Others          | 11          |             |              |

### TABLE 2 | Detailed comparison of sensitivity obtained by Nano-cytology and UCT for BCa detection in relation to tumor stages and grades.

| Tumors          | Nano-cytology | UCT   | \( p \)-value |
|-----------------|---------------|-------|--------------|
|                 | \( n \) Positive/\( n \) Total | Sensitivity (%) | \( n \) Positive/\( n \) Total | Sensitivity (%) |
| BC              | 84/102        | 82.4  | 61/102       | 59.8  | .001* |
| BC by grade     |               |       |              |       |      |
| Low             | 34/43         | 79.1  | 17/43        | 39.5  | .000* |
| TaLG            | 27/34         | 79.4  | 9/34         | 26.5  | .000* |
| T1LG            | 6/7           | 85.7  | 6/7          | 85.7  | 1     |
| T2–4LG          | 1/2           | 50.0  | 2/2          | 100.0 | .248  |
| High            | 50/59         | 84.7  | 44/59        | 74.6  | .253  |
| TaHG            | 9/12          | 75.0  | 8/12         | 66.7  | .653  |
| T1HG            | 28/32         | 87.5  | 25/32        | 78.1  | .320  |
| T2–4HG          | 13/15         | 86.7  | 11/15        | 73.3  | .361  |
| BC by stage     |               |       |              |       |      |
| \(<pT2\)        | 70/85         | 82.4  | 48/85        | 56.5  | .000* |
| Ta               | 36/46         | 78.3  | 17/46        | 37.0  | .000* |
| T1               | 34/39         | 87.2  | 31/39        | 79.5  | .362  |
| \(\geq pT2\)    | 14/17         | 82.4  | 13/17        | 76.5  | 1.000 |
| Control         |               |       |              |       |      |
| All             | 44/49         | 89.8  | 49/49        | 100.0 | .022* |
| Normal          | 32/32         | 100.0 | 32/32        | 100.0 | 1     |
| Infection       | 12/17         | 70.6  | 17/17        | 100.0 | .003* |
| PPV             | 94.3%         |       |              | 100%  |      |
| NPV             | 71.0%         |       |              | 54.4% |      |

NPV, negative predictive value; PPV, positive predictive value.

*Significant, \( p < .05 \).
Birkhahn et al. (2013) invented a novel portable microfiltration device for the capture, enumeration, and characterization of exfoliated tumor cells in urine. Sensitivity (53.3% vs. 40.0%) and specificity (100% vs. 95.8%) of microfilter cytology were higher than standard cytology. Miyake et al. (2021) created a high-throughput detection device for hexylaminolevulinate-mediated fluorescent voided urine cytology, and this novel approach was found to have significantly higher sensitivity compared with standard cytology (63% vs. 29%).

Over the last few decades, numerous studies have tried to explore novel techniques to detect urothelial carcinoma by analyzing protein and nucleic acid in urine. Several methods such as bladder tumor antigen, FISH, and NMP22 have been approved by the FDA. However, clinical application of these markers is still rare due to the lower specificity compared with UCT and the low reproducibility. None of these markers have been accepted for diagnosis or follow-up in daily practice or clinical guidelines (Babjuk et al., 2022). More recently, several detection platforms based on high-throughput sequencing have been developed, such as CxBladder (Kavalieris et al., 2016) and Xpert (Valenberg et al., 2019) (multigene expression markers); Bladder EpiCheck (Mancini et al., 2020), UriFind (Ruan et al., 2021), and utMeMA (Chen et al., 2020) (DNA methylation markers); and UroCAD (Chromosomal instability) (Zeng et al., 2020). These novel markers were reported to have both high sensitivity and specificity and NPV. Valenberg et al. (2019) developed the Xpert Bladder Cancer Monitor (Xpert) and measured five mRNA targets (ABL1, CRH, IGF2, UPK1B, and ANXA10) that are frequently overexpressed in BC. The overall sensitivity was 74% (63% for LG, 83% for HG) and specificity was 80%. Ruan et al. (2021) developed and validated a urine-based PCR DNA methylation assay for early detection of BC, which showed a sensitivity of 88.1%–91.2%, a specificity of 89.7%–85.7%, and superior sensitivity in detecting low-grade (66.7%–77.8%) and Ta tumors (83.3%). Compared with these detection platforms based on the high-throughput sequencing, nano-cytology showed similar sensitivity for low-grade (79.1%) and Ta tumors (78.3%). However, these liquid biopsy methods are still not widely used in clinical practice; further studies with a larger sample size in multiple centers and longer follow-up are warranted.

Nanotechnology has widely been developed for the management of cancers from diagnosis to treatment (Tomlinson et al., 2015). However, nanotechnology applied on the noninvasive detection of BC is limited. Eissa et al. (2014) described a gold nanoparticle assay in which target RNA was purified using magnetic nanoparticles (Fe3O4) and then detected with standard molecular techniques. This approach reached a sensitivity of 88.5% and a specificity of 94%. Hyaluronanase was detected in urine based on the agglomeration characteristics of cationic gold nanoparticles to diagnose BC in 40 participants; this study showed that the sensitivity was 90% and the specificity was 80.8% when the threshold value was 93.5 μU/ng protein (Nossier et al., 2013). Nossier et al. (2016) developed a simple colorimetric gold nanoparticle assay for the detection of urinary total gelatinase activity (MMP-2 and MMP-9) to differentiate BC patients, and resulted in a sensitivity of 87.5% and a specificity of 86.4%.

Based on the fact that the tumor cell membrane is negatively charged, nanoparticles with positive electricity are more conducive to bind to the cell membrane (Chen et al., 2016; Hla et al., 2021). Inspired by unlike electric charges attract, we utilized the positively charged mNPs to capture tumor cells in urine. The morphology of low-grade tumor cells is not much different from normal urothelium. As a result, it is difficult to identify low-grade tumor cells with plenty of background cells, which leads to lower sensitivity compared to high-grade tumor cells in standard UCT (Barkan et al., 2016). The Nano-cytology method could identify tumor cells by the nano-ring phenomenon and enrich tumor cells and reduce the influence of a large number of background cells in exfoliated cell slides, thus improving the reading efficiency and accuracy of cytopathologists.

Limitations of the present study should be noted. First, mNPs are synthesized and provided by the laboratory we worked with, and nano-cytology is currently only available in our hospital. As a result, this is a single-center study. Second, only a small number of urine samples were included in the present study, and the value of nano-cytology should be confirmed via a larger cohort and multicenter study in the future. Third, Nano-cytology was the combination of the “nano-ring” phenomenon and the cytology test of the mNP-enriched cells. Compared with UCT, the cytology test of mNP enrichment lost some of the urine exfoliated cells. Fourth, nano-ring is essential to capture tumor cells, but we have found that mNPs could also be absorbed by few leukocytes such as granulocytes in a previous study (Chen et al., 2016). In the present study, five patients with a false-positive result (nano-ring phenomenon on white blood cells) were found to have a high level of sensitivity.
of white blood cells in urine (at least 280 cells/HPF). Predictably, the diagnostic accuracy can be influenced in patients with severe urinary tract infection, and nano-cytology should be conducted after infection is under control. Fourth, although mNPs are specific for tumor cells, they cannot capture tumor cells less than 50/50 ml; the lack of sufficient exfoliative cells in urine from patients may be the major technique limitation. So, the combination of nano-cytology and UCT will help to improve detection sensitivity. Fifth, we did not compare the diagnostic performance of nano-cytology with FISH assay, because urine sample collected at one urination is not enough for three urine tests, and urine collected at different times may further introduce bias.

**CONCLUSION**

Compared with standard UCT, the Nano-cytology assay showed significantly improved sensitivity and comparable specificity for detecting BC. Nano-cytology may be a promising novel approach adjunct to cystoscopy for diagnosis of BC in clinical practice.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article supplementary material. Further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Shanghai Changhai Hospital. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Shanghai Changhai Hospital. The animal study was reviewed and approved by Shanghai Changhai Hospital. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Shanghai Changhai Hospital.

**REFERENCES**

Babjuk, M., Burger, M., Compérat, E. M., Gontero, P., Mostafid, A. H., Palou, J., et al. (2019). European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur. Urol. 76 (5), 639–657. doi:10.1016/j.eururo.2019.08.016

Babjuk, M., Burger, M., Compérat, E. M., Gontero, P., Mostafid, A. H., Palou, J., et al. (2022). European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer (Ta, T1, and Carcinoma In Situ). Eur. Urol. 81 (1), 73–94.

Barkan, G. A., Wojcik, E. M., Nayar, R., Savic-Prince, S., Quek, M. L., Kurtycz, D. F. L., et al. (2016). The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology. J. Am. Soc. Cytopathol. 5 (3), 177–188. doi:10.1016/j.jasc.2016.04.005

Birkhahn, M., Mitra, A. P., Williams, A. J., Barr, N. J., Skinner, E. C., Stein, J. P., et al. (2013). A Novel Precision-Engineered Microfiltration Device for Capture and Characterisation of Bladder Cancer Cells in Urine. Eur. J. Cancer 49 (15), 3159–3168. doi:10.1016/j.ejca.2013.04.033

Chen, B., Le, W., Wang, Y., Li, Z., Wang, D., Ren, L., et al. (2016). Targeting Negative Surface Charges of Cancer Cells by Multifunctional Nanoprobes. Theranostics 6 (11), 1887–1898.

**AUTHOR CONTRIBUTIONS**

JX: Conceptualization, resources, data curation, supervision, funding acquisition, writing—original draft, writing—review and editing. SZ: Resources, data curation, investigation, writing—original draft, writing—review and editing. JL: Conceptualization, data curation, investigation. LG: Resources, supervision, data curation. WL: Conceptualization, data curation, supervision, methodology. XH: Conceptualization, supervision, methodology. GW: Data curation. BC: Conceptualization, data curation, supervision, funding acquisition. ZZ: Conceptualization, data curation, supervision, funding acquisition, investigation. CX: Conceptualization, data curation, supervision, funding acquisition, writing—original draft, writing—review and editing.

**FUNDING**

This research was financed by grants from Precision Medicine Translational application Research Project of Naval Medical University (2017JZ16 and 2017JZ33), grants from the Qihang program of Naval Medical University, Discipline development plan in Changhai Hospital (2019YXK041), Medical innovation research special project of Shanghai (20Y11904800), Shanghai Health Commission health industry clinical research project (201940177), and the National Natural Science Foundation of China (81572509, 81772720, 81802515, 81972391, and 82172871).

**ACKNOWLEDGMENTS**

We thank YanLei Chu, the secretary of the Department of Urology in Changhai Hospital, for her assistance in collecting and sending urine samples used in the study.

Chen, X., Zhang, J., Ruan, W., Huang, M., Wang, C., Wang, H., et al. (2020). Urine DNA Methylation Assay Enables Early Detection and Recurrence Monitoring for Bladder Cancer. J. Clin. Invest. 130 (12), 6278–6289. doi:10.1172/JCI139997

Compérat, E., Larrié, S., Roupret, M., Neuzillet, Y., Pignot, G., Quintens, H., et al. (2015). Clinicopathological Characteristics of Urothelial Bladder Cancer in Patients Less Than 40 Years Old. Virchows Arch. 466 (5), 589–594. doi:10.1007/s00428-015-1739-2

Dimashkieh, H., Wolff, D. J., Smith, T. M., Houser, P. M., Nietert, P. J., and Yang, J. (2013). Evaluation of Urovysion and Cytology for Bladder Cancer Detection: a Study of 1835 Paired Urine Samples with Clinical and Histologic Correlation. Cancer Cytopathol 121 (10), 591–597. doi:10.1002/cncy.21327

Eissa, S., Shawky, S. M., Matboli, M., Mohamed, S., and Azzazy, H. M. (2014). Direct Detection of Unamplified Hepatoma Upregulated Protein RNA in Urine Using Gold Nanoparticles for Bladder Cancer Diagnosis. Clin. Biochem. 47 (1–2), 104–110. doi:10.1016/j.clinbiochem.2013.10.022

Grossman, H. B., Messing, E., Soloway, M., Tomera, K., Katz, G., Berger, Y., et al. (2005). Detection of Bladder Cancer Using a point-of-care Proteomic Assay. JAMA 293 (20), 810–816. doi:10.1001/jama.293.7.810

Miyake, M., Nakai, Y., Nishimura, N., Ohnishi, S., Oda, Y., Fujii, T., et al. (2021). Hexylaminolevulinate-Mediated Fluorescent Urine Cytology with a Novel Automated Detection Technology for Screening and Surveillance of Bladder Cancer. BJU Int. 128 (2), 244–253. doi:10.1111/bju.15368
Hla, B., Cma, B., and Xd, B. (2021). Rapid Visualizing and Pathological Grading of Bladder Tumor Tissues by Simple Nanodiagnostics. Biomaterials, 264, 120434. doi:10.1016/j.biomaterials.2020.120434

International Agency for Research on Cancer (2021). Estimated Number of New 959 Cases in 2020. Worldwide, Both Sexes, All Ages. Geneva, Switzerland: World Health Organization.

Kavalieris, L., O’Sullivan, P., Frampton, C., Guilford, P., Darling, D., Jacobson, E., et al. (2016). Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J. Urol., 197, 1419–1426. doi:10.1016/j.juro.2016.12.010

Mancini, M., Righetto, M., Zumerle, S., Montopoli, M., and Zattoni, F. (2020). The Bladder Epithelial-Cytosol In Vitro Test as a Non-invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence. Int. J. Mol. Sci., 21 (18), 6542. doi:10.3390/ijms21186542

Nossier, A. I., Eissa, S., Ismail, M. F., Hamdy, M. A., and Azzazy, H. M. (2013). A Review of Published Evidence. Int. J. Mol. Sci., 21 (18), 6542. doi:10.3390/ijms21186542

Ruan, W., Chen, X., Huang, M., Wang, H., Chen, J., Liang, Z., et al. (2021). A Nanotechnology in Human Health Care. Nanomedicine, 10 (7), 1189–1201. doi:10.2217/nmm.14.212

Valenberg, F. J. P. v., Hiar, A. M., Wallace, E., Bridge, J. A., Mayne, D. J., Beqaj, S., et al. (2019). Prospective Validation of an mRNA-Based Urine Test for Surveillance of Patients with Bladder Cancer. Eur. Urol., 75 (5), 853–860. doi:10.1016/j.euro.2018.11.055

Witjes, J. A., Bruins, H. M., Cathomas, R., Compérat, E. M., Cowan, N. C., Gakis, G., et al. (2021). European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur. Urol., 79 (1), 82–104. doi:10.1016/j.euro.2020.03.055

Xu, C., Xu, W., Ren, S., Wu, C., Wang, F., Lu, J., et al. (2013). Establishment of a Chinese Bladder Cancer Cell Line (T921) with High Metastatic Activity. In Vitro Cell Dev. Biol. Anim., 499, 668–678. doi:10.1007/s11626-013-9651-z

Yafi, F. A., Brimo, F., Steinberg, J., Apríkian, A. G., Tanguay, S., and Kassouf, W. (2015). Prospective Analysis of Sensitivity and Specificity of Urinary Cytology and Other Urinary Biomarkers for Bladder Cancer. Urol. Oncol., 33 (2), 66e25–31. doi:10.1016/j.urolonc.2014.06.008

Zeng, S., Ying, Y., Xing, N., Wang, B., Qian, Z., Zhou, Z., et al. (2020). Noninvasive Detection of Urothelial Carcinoma by Cost-Effective Low-Coverage Whole-Genome Sequencing from Urine-Exfoliated Cell DNA. Clin. Cancer Res., 26 (21), 5646–5654. doi:10.1158/1078-0432.ccr-20-0401

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xu, Zeng, Li, Guo, Le, Huang, Wang, Chen, Zhang, and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.